About Scott Zimmerman

This author has not yet filled in any details.
So far Scott Zimmerman has created 66 blog entries.

Don’t use generic Lyrica for pain, Pfizer warns U.K. providers–or else

By |2017-04-25T18:03:49+00:00January 15th, 2015|Uncategorized|

Pharma giant cites 2017 use patent in urging docs, pharmacists to stay away January 15, 2015 | By Tracy Staton Usually, when generic copies of a branded drug hit the market, that's the end of the line for scrapping over patent protection. And usually, when drugmakers are trying to protect their patents, they don't go [...]

Comments Off on Don’t use generic Lyrica for pain, Pfizer warns U.K. providers–or else

Novartis Pharmaceuticals announces a joint investment company with Qualcomm

By |2017-04-25T18:03:49+00:00January 14th, 2015|Uncategorized|

Novartis Pharmaceuticals has announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients. "By working with Qualcomm Ventures, Novartis sees the opportunity to take a greater leadership role in introducing new mobile or [...]

Comments Off on Novartis Pharmaceuticals announces a joint investment company with Qualcomm

Stocks and Commodities Head South – Holiday Sales Failed. Pharma Holds Tight!

By |2015-01-14T16:17:53+00:00January 14th, 2015|Pharma News|

I really have no idea where the markets are going. In fact, I'm surprised and dumbfounded how the markets have surged to these levels at all. Never doubt the power behind the FED and the massive CASH print machine. Are we in danger zone? Not Yet!. Watch for a break of 17,000 on the INDU. It [...]

Comments Off on Stocks and Commodities Head South – Holiday Sales Failed. Pharma Holds Tight!

Shire to buy biopharma company, NPS Pharma for $5.2 billion, up 80% from October

By |2017-04-25T18:03:50+00:00January 12th, 2015|Pharma News|

NPS up 80% from October - Some secrets obviously don't stay in the board room? Shire and NPS Pharmaceuticals, announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 [...]

Comments Off on Shire to buy biopharma company, NPS Pharma for $5.2 billion, up 80% from October

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

By |2017-04-25T18:03:50+00:00January 9th, 2015|Pharma News|

VRTX - 44% Ramp from August - How much more of a Premium for a Pharma bid?   NEW YORK (TheStreet) -- My biotech stock predictions for 2015. (BY David Sobek) 1. Drug pricing fears finally catch up to the biotech sector and the multi-year bull market ends. However, the closely watched biotech stock indices churn up [...]

Comments Off on Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

By |2017-04-25T18:03:50+00:00January 9th, 2015|Pharma News|

By Emily Wasserman A new voice is joining the patent-fighting chorus. U.S. hedge fund manager Kyle Bass, best known for predicting the subprime mortgage crisis in 2008, said he plans to challenge "questionable" drug patents held by industry heavyweights. Bass plans to challenge 15 drug companies' patents via an Inter Partes Review (IPR) process created [...]

Comments Off on Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

Increases in Women’s Clinical Trial Participation Bring Uneven Gains

By |2017-04-25T18:03:50+00:00January 8th, 2015|Pharma News|

by Anette Breindl, PhD Twenty-four years after the National Institutes of Health (NIH) established the Office of Research on Women’s Health, and 21 years after the NIH Revitalization Act of 1993 first required that women be included in clinical trials, certainly the letter of the law has been achieved. Women are now the majority of participants [...]

Comments Off on Increases in Women’s Clinical Trial Participation Bring Uneven Gains

Cancer-fighting CytomX lands $20 million Pfizer investment, makes key hires

By |2017-04-25T18:03:50+00:00January 7th, 2015|Pharma News|

CytomX Therapeutics Inc. grabbed $20 million led by Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio. The investment, disclosed Tuesday, comes after CytomX on Monday announced a trio of key hires, including former Five Prime Therapeutics chief scientific officer Dr. [...]

Comments Off on Cancer-fighting CytomX lands $20 million Pfizer investment, makes key hires
Go to Top